AstriVax Therapeutics

Best-in-class virus-targeted immunotherapies in oncology and beyond  

Astrivax Therapeutics (Astrivax) is a clinical-stage biopharmaceutical company on a mission to end virus-driven cancer, the second leading preventable cause of cancer after smoking. Its clinically validated Launch-iT platform generates durable, antigen-specific T-cell responses that clear virus-infected cells, supported by a scalable, tech-transfer–ready manufacturing process. 

Astrivax’s lead program targets human papillomavirus 16 (HPV16), a leading cause of virus-driven cancers, including cervical cancer and head and neck cancer. The company is advancing its platform toward clinical proof-of-concept for persistent HPV infections and plans to expand across additional HPV-driven cancers. Beyond oncology, Astrivax is exploring applications in autoimmune diseases where viral infections are increasingly recognized as drivers of disease.